Baxfendy recommended for approval in the EU

AI SummaryClose X

AstraZeneca's Baxfendy has received a positive CHMP opinion recommending EU approval for adults with hypertension uncontrolled on ≥2 antihypertensives; Phase III results showed Baxfendy 2mg reduced office seated SBP by 15.7 mmHg from baseline (placebo‑adjusted −9.8 mmHg; 95% CI −12.6 to −7.0; p<0.001) and 24‑hour ambulatory SBP by 16.6 mmHg (placebo‑adjusted −14.0 mmHg; 95% CI −17.2 to −10.8; p<0.0001), with 70.6% achieving <130 mmHg versus 16.7% on placebo (OR 15.2; p<0.0001; NNT=2), a sustained 52‑week placebo‑adjusted reduction of 12.6 mmHg, and no unexpected safety findings, supporting a first‑in‑class commercial opportunity in ~70 million Europeans with uncontrolled hypertension.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings